The lead structure in cardiac glycosides is 5 beta, 14 beta-androstane-3 beta 14-diol.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print Cited Medium: Print ISSN: 0028-1298 (Print) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE

Original Publication: Berlin, New York, Springer Verlag.

Sodium-Potassium-Exchanging ATPase*; Androstane-3,17-diol/*analysis ; Androstanols/*analysis ; Cardiac Glycosides/*analysis ; Receptors, Drug/*metabolism; Androstane-3,17-diol/analogs & derivatives ; Animals ; Binding Sites ; Carbohydrate Conformation ; Cardiac Glycosides/metabolism ; Chemical Phenomena ; Chemistry ; Guinea Pigs ; Humans ; Male ; Mathematics ; Protein Conformation ; Structure-Activity Relationship

The purpose of the present study was to determine the lead structure in cardiac glycosides at the receptor level, i.e. the minimal structural requirement for specific and powerful receptor recognition. Accordingly 73 digitalis-like acting steroids were characterized as to the concentration effecting half-maximum inhibition of Na,K-ATPase from human cardiac muscle under standardized turnover conditions. Since the Ki value equaled the apparent KD value, K'D was expressed in terms of the apparent standard Gibbs energy change delta G degrees' of steroid interaction with Na,K-ATPase. This allowed the use of the extrathermodynamic approach as a rational way of correlating in a quantitative manner, the potency and structure of the various steroidal compounds. The results of the present analysis taken in conjunction with relevant findings reported in the literature, favour the following conclusions. Cassaine, canrenone, prednisolone- and progesterone-3,20-bisguanylhydrazone, and chlormadinol acetate are compounds that are not congeneric with digitalis. The butenolide ring of cardenolides or the analogous side-chains at C17 beta of 5 beta, 14 beta-androstane-3 beta, 14-diol are not pharmacophoric substructures, but merely amplifiers of the interaction energy of the steroid lead. All modifications of the structure, geometry and spatial relationship between the steroid nucleus and butenolide side chain of digitoxigenin all at once weaken the close fit interaction with the steroid and butenolide binding subsites of the enzyme in such way that the cardenolide derivatives interact with the receptor binding site area in whatever orientation that will minimize the Gibbs energy of the steroid-receptor-solvent system. The "butenolide carbonyl oxygen distance model" (Ahmed et al. 1983) for the interpretation of the differences in potency of the cardenolide derivatives describes the change in interaction energy through structural modification as a function of the entire molecule. 5 beta, 14 beta-androstane-3 beta, 14-diol, the steroid nucleus of cardiac glycosides of the digitalis type, is the minimum structure for specific receptor recognition and the key structure for inducing protein conformational change and thus Na,K-ATPase inhibition. It is also the structural requirement for maximum contributions of the butenolide substituent at C17 beta and the sugar substituent at C3 beta-OH to the overall interaction energy, i.e. this steroid nucleus is the lead structure.(ABSTRACT TRUNCATED AT 400 WORDS)

J Med Chem. 1973 Dec;16(12):1370-6. (PMID: 4765863)
Eur J Pharmacol. 1978 May 15;49(2):121-32. (PMID: 149010)
Biochem Pharmacol. 1984 Jul 1;33(13):2089-99. (PMID: 6331458)
Biochem Pharmacol. 1983 Sep 15;32(18):2767-74. (PMID: 6313008)
Mol Pharmacol. 1980 Jul;18(1):53-6. (PMID: 6251358)
J Pharmacol Exp Ther. 1959 Jan;125(1):40-8. (PMID: 13621390)
Eur J Pharmacol. 1978 Sep 1;51(1):63-9. (PMID: 212278)
Biochem Pharmacol. 1965 Dec;14(12):1785-802. (PMID: 4222534)
Planta Med. 1971;:Suppl 4:66-78. (PMID: 4263704)
Eur J Pharmacol. 1978 Aug 15;50(4):409-18. (PMID: 212275)
J Biol Chem. 1982 May 25;257(10):5601-6. (PMID: 6279607)
Acta Biol Med Ger. 1970;24(6):K67-72. (PMID: 4249241)
Science. 1981 Feb 13;211(4483):661-6. (PMID: 7455704)
Eur J Pharmacol. 1979 Dec 20;60(4):329-36. (PMID: 230981)
Anal Biochem. 1976 Jan;70(1):241-50. (PMID: 1259145)
Pharmazie. 1982 Dec;37(12):827-8. (PMID: 6298840)
Biochim Biophys Acta. 1966 Nov 15;128(2):380-90. (PMID: 4226404)
J Pharmacol Exp Ther. 1963 Nov;142:215-22. (PMID: 14079658)
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1969;263(1):46-59. (PMID: 4240936)
J Med Chem. 1984 Mar;27(3):256-61. (PMID: 6321733)
Arzneimittelforschung. 1977;27(3):642-9. (PMID: 577437)
Arch Biochem Biophys. 1980 Jul;202(2):442-9. (PMID: 6257168)
Arzneimittelforschung. 1984;34(5):572-4. (PMID: 6540575)
J Biol Chem. 1983 Jul 10;258(13):8092-7. (PMID: 6305971)
J Pharmacol Exp Ther. 1981 Jun;217(3):784-90. (PMID: 6262496)
J Med Chem. 1978 Mar;21(3):284-8. (PMID: 146738)
Eur J Biochem. 1967 May;1(3):334-43. (PMID: 4228756)
J Med Chem. 1982 Oct;25(10):1222-6. (PMID: 7143360)
Arzneimittelforschung. 1983;33(9):1215-8. (PMID: 6685501)
J Mol Biol. 1984 Mar 25;174(1):175-91. (PMID: 6371249)
Arzneimittelforschung. 1983;33(6):814-7. (PMID: 6684433)
Arch Int Pharmacodyn Ther. 1976 Jun;221(2):339-41. (PMID: 134678)
Circ Res. 1980 Jun;46(6 Pt 2):I167-72. (PMID: 6445795)
Arzneimittelforschung. 1978;28(3a):531-5. (PMID: 148278)
Acta Biol Med Ger. 1972;28(6):935-56. (PMID: 4264261)
Biochemistry. 1978 Aug 8;17(16):3201-8. (PMID: 567487)
J Pharm Sci. 1974 Nov;63(11):1649-83. (PMID: 4279283)
Arzneimittelforschung. 1964 Oct;14:1073-7. (PMID: 14346985)
Mol Pharmacol. 1981 Nov;20(3):551-7. (PMID: 6173736)
Eur J Pharmacol. 1975 Jun-Jul;32(02):133-45. (PMID: 125204)
Science. 1979 Apr 27;204(4391):375-80. (PMID: 220706)
Naunyn Schmiedebergs Arch Pharmacol. 1974;283(4):335-56. (PMID: 4278432)
Mol Pharmacol. 1980 Nov;18(3):402-5. (PMID: 7464804)
Arzneimittelforschung. 1981;31(7):1059-64. (PMID: 7196752)
Prog Drug Res. 1979;23:97-198. (PMID: 397526)

0 (Androstanols)
0 (Cardiac Glycosides)
0 (Receptors, Drug)
0 (cardiac glycoside receptors)
25126-76-5 (Androstane-3,17-diol)
98753-27-6 (androstane-3,14-diol)
EC 7.2.2.13 (Sodium-Potassium-Exchanging ATPase)

Date Created: 19850601 Date Completed: 19851015 Latest Revision: 20191210

20240829

10.1007/BF00496377

4033807